Everest Ventures

Everest Ventures is a finance advisory and investment management firm that focuses on small and medium enterprises (SMEs). The company emphasizes a sustainable business approach rooted in traditional values while promoting customer-centricity, agility, and diversity. It leverages critical thinking and technology to provide tailored solutions for its clients and fosters strategic collaborations to enhance its service offerings.

Neo Maruatona Ratau

Founder and Chair

5 past transactions

Legendsemi

Series A in 2023
Legendsemi specializes in the development and design of high-performance analog and mixed-signal chips. The company is dedicated to researching and creating mid-to-high-end digital-analog hybrid products, focusing on semiconductor solutions that primarily address high-precision signal chains and signal chain microcontrollers and system-on-chips. By leveraging advanced technology, Legendsemi aims to deliver innovative products that meet the needs of its users in the semiconductor market.

Evrynet

Venture Round in 2021
Evrynet is a developer of an innovative financial services platform that facilitates the creation of centralized and decentralized finance (CeDeFi) applications. The company utilizes blockchain technology to offer foundational financial templates, allowing developers and businesses to construct complex financial functions and decentralized finance applications. Its platform incorporates smart contracts, which enable users to create financial applications that seamlessly interact with various leading blockchains. By providing this infrastructure, Evrynet empowers individuals and enterprises to build a wide range of financial solutions, enhancing interoperability within the financial ecosystem.

XCarnival

Seed Round in 2021
XCarnival is a company focused on the crypto sector, functioning as a crypto influencer while also developing a synthetic asset platform. This platform offers users exposure to a variety of cryptocurrencies through synthetic markets that facilitate asset swapping. Additionally, XCarnival provides limited market options and a brokerage service designed to optimize and liquidate assets. By enabling investments in NFT assets without direct involvement in their underlying assets, XCarnival aims to create innovative solutions for asset leasing, pawning, and lending within the cryptocurrency ecosystem.

7SIGNAL

Series D in 2020
7SIGNAL specializes in enterprise wireless experience monitoring, offering a cloud-based platform that continuously tracks the performance of wireless networks. This system is designed to identify performance issues that affect application functionality, focusing on the critical interactions at the edge of Wi-Fi networks where user experience is paramount. By employing an "outside-in" approach, 7SIGNAL provides insights that enhance employee productivity, streamline operations, and improve return on investment for network infrastructure. The platform is utilized by a diverse range of clients, including innovative organizations, educational institutions, healthcare systems, and government agencies, and is currently deployed in Fortune 500 companies and large venues around the world. Additionally, it aids IT enterprises in managing the end-user Wi-Fi experience, reducing the total cost of ownership for wireless LANs by improving troubleshooting efficiency and baseline performance without the need for additional access points.

Suzhou Ribo Life Science

Series C in 2020
Suzhou Ribo Life Science Co., Ltd. specializes in the development of nucleic acid drugs utilizing RNA interference (RNAi) technology, with a particular focus on treating liver diseases. Founded in 2007 and based in Kunshan, China, the company engages in various aspects of drug development, including drug discovery, siRNA design and screening, chemical modification, delivery technology, pharmacodynamics and pharmacokinetics studies, safety evaluation, and clinical trials. Suzhou Ribo Life Science offers siRNA therapeutics targeting conditions such as Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, and HIV. The company has established a strategic partnership with Quark Pharmaceuticals, Inc. to enhance its research and development capabilities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.